Welcome to the Oncology Brothers podcast! In this episode, we were joined by Dr. Samuel Klempner, a GI medical oncologist from the Massachusetts General Hospital, to discuss the evolving treatment landscape for upper gastrointestinal cancers, specifically esophageal, gastroesophageal junction (GEJ), and gastric adenocarcinoma.
During our discussion we touched on:
The treatment algorithm for localized disease, including the shift from local therapy to a combination of systemic and local treatments
The current standard of care, which includes perioperative durvalumab with the FLOT regimen and surgery
The role of chemoradiation therapy for patients who are not surgical candidates and the nuances of managing residual disease
The importance of biomarker-driven treatment in metastatic disease, focusing on HER2 status, PD-L1 scores, and CLDN18.2 expression
The latest advancement, the approval of zanidatamab and clinical implications for treatment strategies
Management of side effects associated with these therapies and the importance of patient quality of life
Whether you're a healthcare professional or someone interested in the latest in cancer care, this episode provides valuable insights into the complexities of treating upper GI cancers.
Podden och tillhörande omslagsbild på den här sidan tillhör
Oncology Brothers. Innehållet i podden är skapat av Oncology Brothers och inte av,
eller tillsammans med, Poddtoppen.
